Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($0.09), $0.99 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $140 thousand versus the consensus estimate of $33.31 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.